Teresa Bitetti, President of Global Oncology at Takeda, shared a post LinkedIn:
“With patient needs at the forefront, we are committed to forming collaborations that can help address treatment gaps across a range of cancers.
Today, I am pleased to share that we have entered into an agreement with Keros Therapeutics to acquire an exclusive license for a promising activin inhibitor currently in development for the treatment of anemia associated with certain Blood Cancers, including Myelodysplastic Syndromes (MDS) and Myelofibrosis (MF).
A heartfelt thank you to all colleagues whose efforts made this deal possible.”
